載入中
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
前收盤價
US$4.47
+US$0.04 · +0.90%
盤中時間採用ET。市場資料可能有所延遲。
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
日內區間
目前US$4.47
52週區間
目前US$4.47
盤中時間採用ET。市場資料可能有所延遲。
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
日內區間
目前US$4.47
52週區間
目前US$4.47
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 85.6萬 USD | 130.6萬 USD | 287.9萬 USD | 134.7萬 USD | 106.9萬 USD |
| 銷貨成本 | 22.5萬 USD | 80萬 USD | 68.3萬 USD | 32.2萬 USD | 3.3萬 USD |
| 毛利 | 63.1萬 USD | 50.6萬 USD | 219.6萬 USD | 102.5萬 USD | 103.6萬 USD |
| 研究與開發 | 218.6萬 USD | 181.5萬 USD | 164.1萬 USD | 280.3萬 USD | 199萬 USD |
| 銷售、一般及管理費用 | 543.8萬 USD | 580.5萬 USD | 613.2萬 USD | 626.8萬 USD | 364.3萬 USD |
| 營業費用 | 938萬 USD | 782.2萬 USD | 796.9萬 USD | 840.5萬 USD | 576.8萬 USD |
| 利息收入 | 20.7萬 USD | 42.1萬 USD | — | 124萬 USD | 1.8萬 USD |
| 利息支出 | 1.1萬 USD | 3萬 USD | 9000 USD | 3.6萬 USD | 1.2萬 USD |
| 折舊和攤銷 | 23.4萬 USD | 48.2萬 USD | 53.8萬 USD | 18.7萬 USD | 3.3萬 USD |
| 營業利益 | −874.9萬 USD | −731.6萬 USD | −577.3萬 USD | −738萬 USD | −576.8萬 USD |
| 淨利 | −1217.9萬 USD | −628.4萬 USD | −512.2萬 USD | −259.2萬 USD | −580.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年3月4日 | 1:9 | — | — |
股票分割 | 2025年7月3日 | 1:21 | — | — |
股票分割 | 2023年9月28日 | 1:26 | — | — |
已生效 2026年3月4日
1:9
已生效 2025年7月3日
1:21
已生效 2023年9月28日
1:26
報告持有此股票曝險的交易所交易基金。
Avantis Emerging Markets Equity ETFAVEM128.09萬—284.09億 USD0.33%US$94.11+0.93%
Avantis Emerging Markets Value ETFAVES21.49萬0.01%15.67億 USD0.36%US$65.56+1.09%
Avantis Emerging Markets Small Cap Equity ETFAVEE12.62萬0.09%1.4億 USD0.42%US$69.865+0.98%
Avantis Emerging Markets ex-China Equity ETFAVXC12.28萬0.03%4.69億 USD0.33%US$82.1546+0.51%Avantis Emerging Markets Equity ETFAVEMAvantis Emerging Markets Value ETFAVESAvantis Emerging Markets Small Cap Equity ETFAVEEAvantis Emerging Markets ex-China Equity ETFAVXCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
